一分钟看懂
这是一项关于白血病的III 期研究，登记的药物或干预包括Biospecimen Collection；Bone Marrow Aspiration；Bone Marrow Biopsy；Computed Tomography；Obinutuzumab；Questionnaire Administration；Venetoclax，当前状态为招募中。登记地点显示中国Birmingham、Anchorage、Fairbanks、Phoenix等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biospecimen Collection；Bone Marrow Aspiration；Bone Marrow Biopsy；Computed Tomography；Obinutuzumab；Questionnaire Administration；Venetoclax · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University of Alabama at Birmingham Cancer Center · Birmingham
- Anchorage Associates in Radiation Medicine · Anchorage
- Anchorage Radiation Therapy Center · Anchorage
- Alaska Breast Care and Surgery LLC · Anchorage
- Alaska Oncology and Hematology LLC · Anchorage
- Alaska Women's Cancer Care · Anchorage
- Anchorage Oncology Centre · Anchorage
- Katmai Oncology Group · Anchorage
- Providence Alaska Medical Center · Anchorage
- Fairbanks Memorial Hospital · Fairbanks
- Cancer Center at Saint Joseph's · Phoenix
- Banner University Medical Center - Tucson · Tucson
- University of Arizona Cancer Center-North Campus · Tucson
- Mercy Hospital Fort Smith · Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs · Hot Springs
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro
- Kaiser Permanente-Anaheim · Anaheim
- Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande
- Kaiser Permanente-Baldwin Park · Baldwin Park
- Kaiser Permanente-Bellflower · Bellflower
- Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank
- Marshall Cancer Center · Cameron Park
- Mercy Cancer Center - Carmichael · Carmichael
- Mercy San Juan Medical Center · Carmichael
- Enloe Medical Center · Chico
- UC Irvine Health Cancer Center-Newport · Costa Mesa
- City of Hope Comprehensive Cancer Center · Duarte
- Mercy Cancer Center - Elk Grove · Elk Grove
- Kaiser Permanente-Fontana · Fontana
- Kaiser Permanente South Bay · Harbor City
公开的入选条件
- * Participants must have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (collectively referred to as CLL throughout) according to the 2018 International Workshop on CLL. Participants must have been diagnosed wit
- * Participants must have CLL-International Prognostic Index (CLL-IPI) score \>= 4 and/or complex cytogenetics (defined as 3+ chromosomal abnormalities)
- * Cytogenetic AND/OR FISH analyses must be completed at a Clinical Laboratory Improvement Act (CLIA)-approved (or laboratories accredited under Accreditation Canada Diagnostics to conduct FISH analyses) laboratory within 18 months prior to registration. At min
- * TP53 gene mutation analysis performed at any CLIA-approved (or laboratories accredited under Accreditation Canada Diagnostics) lab (if completed) must be obtained within 18 months prior to registration. This sequencing test is distinct from FISH studies for
- Note: TP53 gene mutation analysis is recommended but not required if the participant meets disease-related study criteria via a combination of risk factors that totals a score of 4 on the CLL-IPI score and/or has complex cytogenetics completed
- * Immunoglobulin heavy chain locus variable (IgVH) gene mutation analysis performed at any CLIA-approved lab (or laboratories accredited under Accreditation Canada Diagnostics) must be obtained prior to registration (at any time prior to registration)
- * Serum beta-2 microglobulin level must be obtained within 28 days prior to registration
- * Participants must not meet any of the IWCLL specified criteria for active CLL therapy
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04269902；登记信息更新于 2026-09-17。